PrEP, doxy-PEP and your skin: the medication nobody asks you about

Almost nothing about HIV pre-exposure prophylaxis shows up on skin. That is worth saying first, because articles like this have a tendency to invent problems.

What has changed is the rest of the prevention package around it. Doxy-PEP is now part of standard sexual health care for a lot of people, and it interacts with light in a way that matters in a practice full of lasers.

What doxy-PEP is

In 2024 the CDC issued clinical guidelines recommending doxycycline postexposure prophylaxis for gay and bisexual men, other men who have sex with men, and transgender women who have had a bacterial sexually transmitted infection diagnosed in the previous 12 months.¹

The regimen is a single 200 mg dose of doxycycline taken as soon as possible within 72 hours after sex, with no more than 200 mg in any 24 hour period. In trials it reduced syphilis by 70 to 73 percent, chlamydia by 70 to 88 percent, and gonorrhea by roughly 43 to 55 percent.¹

Those are substantial numbers for a simple intervention, which is why uptake has been fast.

The part that matters here

Doxycycline is photosensitizing. The CDC guidelines list photosensitivity among its common side effects alongside gastrointestinal symptoms.¹

A systematic review of doxycycline phototoxicity describes reactions ranging from a mild sunburn-like sensation with burning and erythema through to large-area photodermatitis, with onycholysis, separation of the nail from its bed, also possible. The reaction is driven mainly by UVA1, wavelengths of 340 to 400 nanometers, and it is dose-related.²

Two honest qualifiers. The same review notes the published literature is thin, so the frequency is not well quantified. And doxy-PEP is episodic rather than daily, so cumulative exposure is far lower than a months-long course of doxycycline for acne, which likely means lower risk.²

Lower is not zero, and the relevant question is not how much you take over a year. It is whether there is doxycycline in your system on the day someone points a laser at your face.

Why intake forms miss it

This is the interesting part, and it is a design problem rather than a patient problem.

Intake forms ask what medications you take. That phrasing assumes a daily pill. Doxy-PEP is taken after an event, sometimes twice a month, sometimes not for six weeks. People taking it correctly and consistently still do not experience it as being on a medication, so they do not write it down.

The fix is on the form, not on you. A question that asks about anything taken in the past two weeks, including as-needed medication, catches it. We made a similar point about intake design in what affirming aesthetic care actually looks like, and this is the same principle: the form determines what the clinician knows before anyone speaks.

What to actually do about it

Nothing dramatic, and nothing that should involve stopping doxy-PEP.

Mention it. If you have taken a dose in the past week or two, say so before a light-based treatment. It is a scheduling detail, not a confession, and a decent clinician will treat it as one.

Expect timing to shift, not treatment to be cancelled. Most light-based treatments can simply be spaced away from a recent dose. Some can proceed with reduced settings. The decision belongs to the clinician who knows the device.

Use sunscreen that actually covers UVA. The phototoxic range is 340 to 400 nanometers, which is the part of the spectrum that many sunscreens cover least well.² Look for broad-spectrum products with high UVA protection, and a tinted formulation with iron oxides if you are also managing pigment.

Watch for the nail sign. Onycholysis is an unusual presentation that people rarely connect to a medication. If your nails start lifting after sun exposure, doxycycline is worth mentioning to whoever is looking at them.

Injectable PrEP and the lumps

Long-acting injectable PrEP has changed the picture for a lot of people, and it produces a visible local reaction that patients often ask about.

In the trials supporting twice-yearly lenacapavir, injection site reactions occurred in 69 percent of participants in one study and 83 percent in the other. Nodules were the most common, at 63 to 64 percent, followed by pain. The majority were mild or moderate, no serious injection site reactions occurred, and incidence declined with subsequent injections.³

A palpable lump at an injection site is therefore the expected outcome rather than a sign something went wrong. It is not something an aesthetics practice should be treating, and anything that is painful, spreading, hot or persistent belongs with the clinician who administered the injection.

The broader point

None of this is a reason for anyone to change their prevention regimen, and it would be a poor trade to reduce protection against HIV or bacterial infection to make a laser appointment simpler.

It is a reason for aesthetic practices to ask better questions. The medication most likely to affect a light-based treatment is the one patients do not think of as medication, and no amount of caution on the patient's side fixes a form that never asks.